A pre-planned subgroup analysis of the ROCKET AF Phase III clinical study confirms that rivaroxaban is highly effective in the prevention of recurrent strokes in patients with atrial fibrillation (AF) who have experienced a prior stroke or transient ischemic attack (TIA).

Nycomed announced results for the first quarter of 2011, demonstrating continued outperformance in the key emerging economies which are driving growth in the global pharmaceuticals industry.

GlaxoSmithKline (GSK) announced further progress on its commitment to reinvest 20% of profits made in the Least Developed Countries (LDCs) back into projects that strengthen the healthcare infrastructure in those countries.

AstraZeneca announced a co-promotion agreement in Japan with Daiichi Sankyo for denosumab for the treatment of bone disorders stemming from bone metastasis.

Eli Lilly and Company (NYSE: LLY) has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica Inc., a newly-formed and privately-held biotechnology company.

Sanofi (EURONEXT: SAN and NYSE: SNY) announced that data from eight compounds in the company's robust oncology portfolio will be showcased in more than 100 abstracts at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2011.

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease.